FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an intermediate for producing a drug conjugate or a pharmaceutically acceptable salt thereof, a method for producing a physiologically active polypeptide conjugate and a drug conjugate for the preparation of drugs or compositions for the prevention, treatment and alleviation of diseases. In one embodiment, the intermediate comprises an immunoglobulin Fc region comprising at the N-terminus a hinge region sequence with the amino acid sequence SEQ ID NO: 8 or 9.
EFFECT: invention expands the arsenal of means for obtaining drug conjugates.
23 cl, 1 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| IMPROVED METHOD FOR HIGH-YIELD PRODUCTION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | 2014 |
|
RU2677796C9 |
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| IMPROVED METHOD FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE PRODUCTION | 2013 |
|
RU2639256C2 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
